Promising Phase I Clinical Trial Results from SENTI-202-101, a Firstin- Class, CD33 and/or FLT3 & not EMCN, Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Adults with R/R AML
1:30 pm - Tuesday 24th March 2026
- SENTI-202 is well tolerated in patients with R/R AML
- SENTI-202 demonstrates promising preliminary efficacy
- Will present data from ≥20 R/R AML patients
